Researchers have for the first time performed a successful bone marrow transplant to cure sickle cell disease in adults, a feat that could expand the procedure to more of the 70,000 Americans with the disease – and possibly some other diseases as well.
About 200 children have been cured of sickle cell with transplants, but the procedure is considered too harsh for adults with severe sickle cell disease. Now a team from the National Institutes of Health and Johns Hopkins University reports in today’s New England Journal of Medicine that it has developed a much less toxic transplant procedure and used it to cure nine of the first 10 patients studied.
“We really don’t have anything else to offer patients with sickle cell disease” who do not respond to hydroxyurea, the only drug useful in treating it, said Dr. John F. Tisdale of the National Heart, Lung and Blood Institute, the senior author of the paper.
The principal drawback to the procedure is that not enough sickle cell patients have a healthy sibling who is a compatible donor.